



- Abril, C., 315
Acevedo-García, D., 321, 331
Adekunle, A. O., 269
Alexander, N. J., 393
Alvarado, R., 57
Alvarez, D., 315
Amaral, E., 87
Ambardekar, S., 33
Anderson, R. A., 357
Aneblom, G., 339
Apaydin, A. M., 459
Archer, D. F., 369
Arowojolu, A. O., 269
Arroll, B., 163
Ashton, J., 387
Avecilla, A., 315
Awini, E., 23
Aydin, M., 459
Aygen, E. M., 211
- Babug, M., 211
Bachar, R., 117
Baiden, F., 23
Baird, D. T., 357
Baker, J. M., 369
Ballagh, S. A., 369
Barnhart, K., 443
Batár, I., 309
Bax, R., 365
Beardsley, L., 169
Becker, D., 261
Berry, D. C., 305
Bersellini, E., 305
Beyth, Y., 105
Bingshun, W., 221
Blanchard, K., 255
Blumberg, G., 117
Bock, J. E., 345
Boesen, H. C., 427
Boldsen, J. L., 153
Bopardikar, A., 33
Borgatta, L., 169
Bowden, M., 365
Brandão, M. A., 289
Brown, A., 251
Bulut, H., 459
Burnhill, M. S., 169
Burruano, B. T., 137
Büscher, U., 439
- Cadiñanos, M., 315
Cao, X., 237
Cardenas, L. H., 215
Castillo, E., 321
Cay, S., 251
Chaki, S. P., 187
Chang, C. V., 289
Changhai, H., 221
Chapman, A., 133
Chaudhury, K., 199
Chen, F. C.-k., 439
Cheng, L., 357
Chiu, P. C. N., 453
Christensen, J. T., 153
Chuang, C., 169
Clark, S., 275
Clarkson, P. M., 67
Clerk, C., 23
Corona, G., 321, 331, 417
Coulter, D., 387
Coyaji, K., 33
Creinin, M. D., 147, 225
Cushman, L. F., 141
- Darney, P. D., 215
De Grava Kempinas, W., 205
Delborge, W., 237
del Castillo, E., 331
Demeyer, F., 411
de Oliveira Guerra, M., 289
Díaz, S., 57
Di Stasi, L. C., 205
Dolder, H., 463
Dominguez, N., 315
Douville, K., 365
Doval, J. L., 315
Dubuisson, J. B., 121
Duncan, G., 73
- Eder, S. E., 147
Ellertson, C., 33, 275, 321, 331, 417
Elomaa, K., 309
Elul, B., 33
Ersheng, G., 221
Exiang, Z., 221
- Fehring, R. J., 231
Felfcio, A. C., 289
Fielding, S. L., 27, 247
- Fisher, M., 117
Fletcher, H., 261
Fong, Y. F., 41
Foote, R. H., 193
Fox, M. C., 225
- Gabelnick, H., 73
García, P., 315
García, S. G., 261
Gaspard, U. J., 411
GESEG: Group for the Study
Follow-up of GyneFIX® in
Spain, 315
Geva, A., 117
Gidoni, Y., 105
Gimenez, E., 315
Giraldo, P. C., 87
Glasier, A., 19, 251
Godwin, A. J., 147
Goldberg, A. B., 215
Goodyear-Smith, F., 163
Gould, H., 417
Graff-Iversen, S., 7
Guha, S. K., 199
Gupta, R. C., 47
Gupta, S., 385
- Harrison-Woolrych, M., 387
Harwood, B., 225
Heimbürger, A., 321, 331
Heinemann, L. A. J., 297
Hendrix, S. L., 393
Henry, D. M., 369
Hernández, G., 315
Herreros, C., 57
Higgins, J., 365
Ho, P.-c., 453
Holzinger, M., 105
Hu, Z.-y., 377
Hubbard, A. E., 215
- Izquierdo, B., 315
- Jagannathan, N. R., 199
Jaisamrarn, U., 407
Janowitz, B., 295
Jespers, V., 133
Jie, Y., 221

- Kallenbach, L., 275
 Kamboj, V. P., 47
 Kaplan, B., 117
 Katz, K., 1
 Kaygusuzoglu, E., 459
 Kazerooni, T., 243
 Kerns, J., 141
 Kettle, H., 251
 Khurana, M., 47
 Kjaer, S. K., 345
 Klein, Z., 105
 Kluff, C., 297
 Knapp, P., 305
 Kook, K., 73
 Kriengsinyot, R., 407
 Krishna, U., 33, 275
 Kuukankorpi, A., 309
- Lal, J., 47
 Langer, A., 321, 331
 Lara-Torre, E., 81
 Larsson, M., 339
 Lech, M. M., 159
 Lee, C. H., 281
 Lefebvre, P., 411
 Li, C., 237
 Liambila, W., 255
 Lifen, X., 179
 Lin, N., 237
 Lingzhi, H., 179
 Lippman, J. S., 147
 Liu, Y.-x., 377
 Loh, S. Y., 41
 Lüdicke, F., 411
 Lukhando, M., 255
- Maat, M. P. M., 297
 Magalhães, J., 87
 Malamud, D., 137, 443
 Mammo, M., 383
 Mandlekar, A., 275
 Markovitch, O., 105
 Martinez, F., 315
 Mauck, C., 221
 Mazaro, R., 205
 McCormick, D., 365
 Mejia, G., 321, 331
 Mirena Study Group, 121
 Misro, M. M., 187
 Morroni, C., 141
 Mosalae, A., 243
 Mugnier, E., 121
 Muia, E., 255
 Murphy, P. A., 141
 Murthy, A., 169
- Nam, N.-y., 27
 Niggemann, B., 439
 Nilas, L., 427
 Nørgaard, M., 427
- Okewole, I. A., 269
 Olenja, J., 255
 Olson, W., 147
 Omar-Fayez, A., 315
 Ostrowska, L., 159
 Otiv, S., 33
 Özdamar, S., 211
- Painter, R., 77
 Paliwal, J. K., 47
 Perslev, A., 427
 Peters, V. M., 289
 Pisal, N., 383
 Pretorius, E. S., 443
- Ramirez, A., 315
 Raote, V., 33, 275
 Rasch, V., 109
 Rauramo, I., 309
 Raymond, E., 295
 Raynor, D. K., 305
 Risvanli, A., 459
 Rodriguez, M. J., 315
 Rodriguez, V., 315
 Rørbye, C., 427
 Rosenberg, M., 365
 Rózsá, M., 433
 Ruiz, C., 315
- Savage, K. J., 67
 Schacht, E., 93
 Schaff, E. A., 27, 247
 Scheen, A., 411
 Schiappacasse, V., 57
 Schiavon, R., 321, 331
 Schlipalius, M. L., 351
 Schnaare, R. L., 137
 Schroeder, B., 81
 Serin, S., 211
 Shaarawy, M., 129
 Shaolan, Z., 179
 Sharma, U., 199
 Shelton, J. D., 15
 Shiyang, W., 179
 Shobokshi, A., 129
 Siljander, M., 309
 Simoes, J. A., 87
 Singh, K., 41
 Singh, M. M., 47
 Song, L., 237
 Sorhaindo, A., 261
 Spannagl, M., 297
 Stanback, J., 1, 295
- Stirling, A., 19
 Svare, E. I., 345
- Taneepanichskul, S., 101, 401, 407
 Tantbiroj, P., 401
 Tejada, M., 315
 Tharnprisan, W., 101
 Thomsen, B. L., 345
 Thonneau, P. F., 385
 Tiezzi, L., 141
 Timbers, K., 443
 Timurkan, H., 459
 Tonstad, S., 7
 Turrado, V., 315
 Tydén, T., 339
- Ugocsai, G., 433
 Ugocsai, P., 433
- Van Damme, L., 133
 Van Dyck, E., 133
 Vessey, M., 77
 Vollenhoven, B. J., 351
 von Essen, L., 339
- Wang, C. H., 453
 Wang, D., 173
 Wang, L., 237
 Wang, Y., 281
 Westergaard, J. G., 153
 Westhoff, C., 141, 247
 Weston, G. C., 351
 Wildemeersch, D., 93, 237
 Wildemeersch, P., 93
 Winikoff, B., 33
- Xianmi, W., 179
 Xiaolan, H., 179
- Yano, C. L., 463
 Yao, Y. Q., 453
 Yeates, D., 77
 Yeung, W. S. B., 453
 Yimin, C., 179
 Yorgev, Y., 117
 Youlun, G., 221
 Yueying, X., 179
 Yulian, L., 179
 Yunzhen, W., 179
- Zepeda, A., 57
 Zhang, W., 237, 237
 Zhang, Z., 237
 Zhang, Z.-h., 377
 Zhao, X., 237
 Zhaohui, L., 179
 Zhou, X.-c., 377
 Zhu, H., 357
 Zou, R.-j., 377

Subject Index
Volume 66
July–December, 2002

- Abortion, profile of women, 41
- Acceptability,
 C31G microbicide formulations, 365
 levonorgestrel-releasing IUS, 121
- Acetaminophen, effect on testis (rat), 463
- Amphotericin B, contraceptive effects (rabbit), 193
- Amphotericin B fungicide, effect on sperm (bull, rabbit), 193
- Anesthesia during surgical abortion, local vs. general, 275
- Attitude survey, male hormonal contraceptives, 351
- Austroplenkia populnea*, effect on reproductive parameters (male rat), 205
- Body weight, effect of ethinylestradiol + gestodene, 159
- Bone mineral density,
 effect of DMPA use, 101
 effect of OC use, 101
- Breastfed infants, effect of mothers with levonorgestrel implants, 57
- C31G hydroxyethyl cellulose gel, safety profile, 369
- C31G microbicide formulations, acceptability trial, 365
- Carbohydrate metabolism,
 effect of ethinylestradiol + gestodene, 411
 effect of ethinylestradiol + desogestrel, 411
- Cauda epididymis extract, use as immunocontraceptive (rat), 459
- Centchroman, interaction with drugs (rat), 47
- Cervical mucus peak day, marker for fertility, 231
- Chlamydia infection, screening at time of emergency contraception, 251
- Clinical experience,
 GyneFix IUS, 315
 Nova T 380, 309
- Clinical guidelines, eligibility for contraceptive methods, 1
- Clinical study,
 ethinylestradiol + gestodene, 407
 ethinylestradiol + levonorgestrel, 401
 ethinylestradiol + norgestimate, 401
- Combined oral contraceptives, approach to hormonal pregnancy testing, 295
- Condoms and latex allergy, 439
- Consensus recommendations, eligibility for contraceptive methods, 1
- Continuation rates, post abortion DMPA, 215
- Contraceptive choices, impact of HIV infection, 87
- Contraceptive failures,
 China, 173
 pregnancy outcomes, 109
- Contraceptive knowledge, mother-daughter communication, 117
- Contraceptive methods,
 effect on Pap smear findings, 243
 failure rate, 173
- Contraceptive use, eligibility criteria, 1
- Copper IUD,
 clinical experience, 309
 effect on cytokines production, 129
- Copper IUS,
 clinical experience, 315
 efficacy, 237
- Cytokines, role in intrauterine contraception, 129
- Depot medroxyprogesterone acetate (DMPA),
 effect on bone mineral density, 101
 pregnancies during use, 169
- Determinants for non-use of contraception, first intercourse, 345
- Dextrin sulfate gel,
 penile application, 133
 vaginal microbicide, 133
- Distribution of vaginal gel, use of MRI, 443
- DMPA (depot medroxyprogesterone acetate),
 DMPA + transdermal estradiol, effect on continuation rate, 215
- DMPA use post abortion, continuation rates, 215
- Drug interactions, effect on centchroman (rat), 47
- Dysmenorrhea, effect of ethinylestradiol + desogestrel + unopposed ethinylestradiol, 393
- Efficacy, GyneFix IUS, 237
- Efficacy calculations, emergency contraception, 19
- Eligibility criteria, contraceptive use, 1
- Emergency contraception
 estimating efficacy, 19
 information campaign, 331
 introduction study, 255
 knowledge and attitudes, 417
 knowledge and use, 427
 levonorgestrel, 269,433
 mifepristone, 221
 mifepristone + tamoxifen, 221
 perception, 23
 screening for chlamydia infection, 251

- survey of knowledge, attitudes and practices, 261, 321
- Emergency contraception and medical abortion, knowledge and attitudes about differences, 417
- Emergency contraceptive pills, over-the-counter experience, 339 repeat use, 15
- Endometrium, effect of levonorgestrel, 433
- Epilepsy and OC use, 77
- Estradiol + DMPA, effect on continuation rate, 215
- Ethinylestradiol + desogestrel, effect on carbohydrate metabolism, 411 effect on dysmenorrhea, 393
- Ethinylestradiol + gestodene, clinical study, 407 effect on body weight, 159 effect on carbohydrate metabolism, 411
- Ethinylestradiol + levonorgestrel, clinical study, 401 effect of imperfect compliance, 147
- Ethinylestradiol + norgestimate, clinical study, 401 effect of imperfect compliance, 147
- Extrauterine mislocated IUD, case reports, 105
- Extrinsic activated protein C resistance and venous thromboembolism, 297
- Failure rate, contraceptive methods, 173
- Female condom, introduction study, 179
- Female controlled drug delivery system, characterization, 281
- Fetal growth, effect of lapachol (rat), 289
- FibroPlant-LNG IUS, 93
- First intercourse, determinants for non-use of contraception, 345
- Follicular activity, effect of OC non-compliance, 147
- Functional ovarian cysts, prevalence, 153
- GyneFix[®], copper IUS, 237, 315
- HIV (human immunodeficiency virus)
- HIV infection, impact on contraception, 87
- Hormonal pregnancy test, revisited, 295
- Hydrogen peroxide, effect on sperm function, 187
- Immunocontraceptive, use of cauda epididymis extract (rat), 459
- Imperfect compliance, effect of OC on follicular activity, 147
- Implant contraceptive, levonorgestrel, 57
- Infant health and growth, effect of mothers with levonorgestrel implants, 57
- Information campaign, emergency contraception, 331
- Initiation of OC use, Quick Start method, 141 Quick Start vs. Sunday Start, 81
- Injectable contraceptive, depot medroxyprogesterone acetate, 101, 169, 215
- Injectable male contraceptive, RISUGTM, 199
- Insertion experience, Multiload Cu 375, 387
- Intrauterine device (IUD), Multiload Cu 375, 387 Nova T[®] 380, 309
- Intrauterine system (IUS) frameless GyneFix[®], 237 GyneFix[®], 315 levonorgestrel-releasing, 93, 121
- Introduction study, emergency contraception, 255 female condoms, 179
- IUD (intrauterine device)
- IUD failure, risk factors, letter to the editor, 385 response to letter to the editor, 385
- IUD perforation, case reports, 105
- IUD prolonged use, case reports, 383 post-menopausal bleeding management, 383
- IUS (intrauterine system)
- Knowledge, attitudes and practices survey, emergency contraception, 261, 321
- Knowledge and attitudes, differences between emergency contraception and medical abortion, 417
- Knowledge and use, emergency contraception, 427
- Lapachol, effect on fetal growth (rat), 289
- Latex allergy and condoms, 439
- Levonorgestrel, effect on breastfed infants, 47 effect on endometrium, 433 effect on sperm functions, 453 emergency contraception, 255, 269 pharmacokinetics, 73
- Levonorgestrel-releasing IUS, 93, 121
- Lipid parameters, effect of progestogen-only contraceptives, 7
- LNG (levonorgestrel)
- Male contraception, testosterone decanoate + etonogestrel implants, 357
- Male contraceptive, RISUGTM, 199
- Male hormonal contraceptives, attitude survey, 351
- Male reproductive parameters, effect of *Austroplenkia populnea* (rat), 205
- Media-promoted fear of health risks, panic-stopping of OCs, 163
- Medical abortion, knowledge and attitudes, 417 mifepristone, 27 mifepristone + misoprostol, 33, 225, 247 use of sonography, 27
- Medical abortion and emergency contraception, knowledge and attitudes about differences, 417
- Metabolic effects, progestogen-only contraceptives, 7
- Methodological quality, eligibility criteria for contraceptive use, 1
- Microbicide, C31G, 365 female controlled drug delivery system, 281
- Mifepristone, emergency contraception, 221 medical abortion, 27

- Mifepristone + misoprostol, medical abortion, 33, 225, 247
- Mifepristone + tamoxifen, emergency contraception, 221
- Mother-daughter communication, use of contraceptives, 117
- MRI (magnetic resonance imaging)
- Multiload Cu 375, experience with insertion, 387
- Muscle damage and recovery, eccentric exercise during OC use, 67
- Natural family planning, peak day of cervical mucus, 231
- Non-use of contraception at first intercourse, determinants, 345
- Nova T 380[®] copper IUD, clinical experience, 309
- Nystatin fungicide, effect on sperm (bull, rabbit), 193
- OC (oral contraceptive)
- OC initiation,
 Quick Start method, 141
 Sunday Start vs. Quick Start, 81
- OC panic-stopping, media-promoted feat of health risks, 163
- OC use,
 effect on bone mineral density, 101
 effect on exercise-induced muscle damage and recovery, 67
- OC use and epilepsy, 77
- Older reproductive age women, use of levonorgestrel-releasing IUS, 121
- One dose vs. two-dose levonorgestrel, emergency contraception, 269
- Oocytes, effect of styrene maleic anhydride (rat), 469
- Oral contraceptive (OC),
 ethinylestradiol + desogestrel, 393, 411
 ethinylestradiol + gestodene, 159, 407, 411
 ethinylestradiol + levonorgestrel, 147, 401
 ethinylestradiol + norgestimate, 401
 thromboembolism risk, 305
 triphasic ethinylestradiol + norgestimate, 147
- Oral vs vaginal misoprostol, following mifepristone, 247
- Ovarian cysts, prevalence, 153
- Ovarian morphology, effect of tubal ligation (rat), 211
- Over-the-counter emergency contraceptive pills, experience, 339
- Panic-stopping of OCs, media-promoted fear of health risks, 163
- Pap smear findings, effect of contraceptive methods, 243
- Paracetamol, effect on testis (rat), 463
- Peak day of cervical mucus, marker for fertility, 231
- Penile application, dextrin sulphate gel, 133
- Perception, emergency contraception, 23
- Perforated IUD, case reports, 105
- Perimenopausal period, use of levonorgestrel IUS, 93
- Pharmacokinetics,
 levonorgestrel, 73
 testosterone decanoate, 357
- Postinor-2, levonorgestrel emergency contraception, 255
- Pregnancy, during use of DMPA, 169
- Pregnancy outcomes, contraceptive failures, 109
- Pregnancy termination, panic-stopping of OCs, 163
- Profile of women seeking abortion, 41
- Progestogen-only contraceptives,
 effect on lipid parameters, 7
 metabolic effects, 7
- Prolonged use of IUD, post-menopausal bleeding management, 383
- Quick Start, OC initiation method, 141
- Quick Start vs. Sunday Start, OC use, 81
- Repeat use, emergency contraceptive pills, 15
- Reproductive parameters, effect of *Austroplenckia populnea* (male rat), 205
- Risk communication, OC users, 305
- RISUG[™], reversible inhibition of sperm under guidance, 199
- Safety profile, C31G hydroxyethyl cellulose gel, 369
- Same day mifepristone + vaginal misoprostol, medical abortion, 225
- Seminal plasma amino acids, effect of RISUG, 199
- Sonography, use in medical abortion, 27
- Sperm, effect of fungicides (bull, rabbit), 193
- Sperm function,
 effect of hydrogen peroxide, 187
 effect of levonorgestrel, 453
- Spermatogenesis, effect of testosterone decanoate + etonogestrel, 357
- Styrene maleic anhydride, effect on oocytes (rat), 469
- Surgical abortion, local vs. general anesthesia, 275
- Testicular cell apoptosis, effect of testosterone undecanoate (monkey), 377
- Testis, effect of paracetamol/acetaminophen (rat), 463
- Testosterone decanoate + etonogestrel,
 effect on spermatogenesis, 357
 pharmacokinetics, 357
- Testosterone undecanoate, effect on testicular cell apoptosis (monkey), 377
- Tubal ligation, effect on ovarian morphology (rat), 211
- Two-dose vs. one dose levonorgestrel, emergency contraception, 269
- Vaginal drug delivery system, characterization, 281
- Vaginal epithelial changes, C31G hydroxyethyl cellulose, 369
- Vaginal gel, MRI to determine distribution, 443
- Vaginal microbicide,
 C31G formulations, 365
 dextrin sulphate gel, 133
- Vaginal vs. oral misoprostol, following mifepristone, 247
- Venous thromboembolism and extrinsic activated protein C resistance, 297
- Venous thrombolism risk, OC use, 305
- Warnings on thromboembolism risk, OC use, 305



